Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Drugs and therapy together: a new hope for anxiety, depression, and more?

NCT ID NCT06993662

Disease control Sponsor: Rakitzi, Stavroula Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This early-stage study is testing whether combining standard psychiatric medications (like antidepressants and anti-anxiety drugs) with individual cognitive behavioral therapy can improve symptoms and daily functioning in people with anxiety, depression, PTSD, OCD, bipolar disorder, schizophrenia, and personality disorders. About 107 participants aged 18-65 will receive the combined treatment in a private practice setting. The study measures changes in thinking, mood, and overall recovery over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
combination of anxiety and depression medications (anxiolytics and antidepressants) plus cognitive behavioral therapy
What this could lead to
If it works, this could point toward a more effective way to manage multiple mental health conditions by combining standard drugs with talk therapy.
What could go wrong
This is a very early Phase 1 study with no control group, so results may not be reliable. The wide range of conditions and lack of blinding make it hard to know if the combination is truly better than either treatment alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

107 people

The number who actually took part.

Started

Jun 2025

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age 18-65, * IQ ≥ 80, * Diagnosis: anxiety disorders, depression, obsessive-compulsive disorders, PTSD, personality disorders, bipolar disorders, schizophrenia and psychotic disorders. Exclusion Criteria: \*Substance abuse and head injury.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anxiety are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety anxiety disorder bipolar disorder Depression depressive disorder obsessive-compulsive disorder personality disorder Personality Disorders post-traumatic stress disorder psychotic disorder Psychotic Disorders schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anxiety Bipolar disorder Depression Obsessive compulsive disorder Personality disorder Psychotic disorders PTSD Schizophrenia

Contacts and locations

Locations

  • Private practice of Dr. S. Rakitzi and Dr. P. Georgila ILISION 34 15771 ATHENS GREECE

    Athens, 15771, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.